What is the recommended first‑line vasopressor and its dosing for a patient with hypotension or shock?

First-Line Vasopressor for Hypotension or Shock

Norepinephrine is the first-choice vasopressor for patients with hypotension or shock, targeting an initial MAP of 65-70 mmHg in most cases. 1

Initial Vasopressor Selection

Norepinephrine stands as the unequivocal first-line agent across multiple international guidelines with strong recommendation and moderate quality evidence 1. This recommendation applies broadly to septic shock and most vasodilatory shock states. The 2025 ESICM guidelines reaffirm this position, emphasizing individualized MAP targets during resuscitation 2.

Dosing Strategy

Starting Dose and Titration

• Begin norepinephrine early to achieve MAP targets rapidly and avoid fluid overload 3
• Titrate to achieve the target MAP, with typical dosing ranges reaching 0.01-3.0 µg/kg/min (though practice varies widely) 4
• Do not delay initiation waiting for complete fluid resuscitation—early vasopressor use prevents prolonged hypotension 3, 5

Blood Pressure Targets

The initial MAP target should be 65-70 mmHg for most patients with septic shock 2, 1. However, adjust this based on:

• Higher targets (MAP >70 mmHg) for:

  • Patients with chronic hypertension showing clinical improvement at higher pressures 2
  • Elevated central venous pressure (CVP) situations where the perfusion gradient (MAP-CVP) is compromised 2
  • Cardiogenic shock (MAP ≥65 mmHg minimum) 2

• Lower targets (MAP 50-60 mmHg) for:

  • Traumatic hemorrhagic shock with uncontrolled bleeding and no traumatic brain injury (systolic 80-90 mmHg) 2

• Higher targets (MAP ≥80 mmHg) for:

  • Traumatic brain injury with Glasgow Coma Score ≤8 2

Second-Line Vasopressor Strategy

When norepinephrine alone proves insufficient, add vasopressin (0.03 units/min) or epinephrine rather than escalating norepinephrine to very high doses 1. The most recent evidence suggests adding vasopressin when norepinephrine reaches 0.25-0.50 µg/kg/min 6, 7, 5.

Vasopressin Addition

• Dose: 0.03 units/min (fixed dose) 1
• Timing: Add when norepinephrine base reaches 0.25-0.50 µg/kg/min rather than continuing to escalate norepinephrine 6, 7
• Purpose: "Decatecholaminization"—reducing catecholamine load and associated adverse effects 6
• Do not use vasopressin as monotherapy for initial treatment 1
• Do not exceed 0.03-0.04 units/min except as salvage therapy 1

Alternative Second-Line Agents

• Epinephrine can be added or substituted when additional agent needed 1
• Dopamine only in highly selected patients with low arrhythmia risk and bradycardia 1
• Phenylephrine reserved for specific circumstances (norepinephrine-induced arrhythmias, high cardiac output states, or salvage) 1

Critical Pitfalls to Avoid

1. Delaying norepinephrine initiation: Start early rather than waiting for complete fluid resuscitation—prolonged hypotension worsens outcomes 3, 5

2. Excessive norepinephrine escalation: Add second-line agents (vasopressin) at moderate norepinephrine doses rather than pushing to very high doses (>1 µg/kg/min) 6, 3, 5

3. Using dopamine for renal protection: This is explicitly not recommended and ineffective 1

4. One-size-fits-all MAP targets: Individualize based on chronic hypertension history, CVP, shock etiology, and clinical response 2

5. Ignoring cardiac function: If persistent hypoperfusion despite adequate MAP and fluids, consider adding dobutamine for inotropic support 1

Monitoring Requirements

Place an arterial catheter as soon as practical in all patients requiring vasopressors for continuous blood pressure monitoring and repeated blood sampling 2, 1. Intermittent cuff measurements are inadequate in hemodynamically unstable shock states 2.

Practical Algorithm

1. Start norepinephrine immediately when hypotension persists despite initial fluid resuscitation
2. Target MAP 65-70 mmHg initially (adjust based on patient factors above)
3. Add vasopressin 0.03 units/min when norepinephrine reaches 0.25-0.50 µg/kg/min
4. Consider epinephrine if additional support needed beyond norepinephrine + vasopressin
5. Add dobutamine if signs of persistent hypoperfusion with adequate MAP suggest cardiac dysfunction
6. Reassess and individualize MAP targets based on clinical response, organ perfusion markers, and patient-specific factors